5 Stock Gainers for Friday: VBI Vaccines, Moderna, Novavax

Stocks trading higher Friday include VBI Vaccines, Moderna, Novavax, Dynavax Technologies, and Quidel.
Publish date:

U.S. stocks finished mixed Friday in the face of slumping U.S. consumer sentiment and escalating rates of coronavirus infections.

Consumer sentiment last month missed economists' forecasts, falling to 73.2 from 78.1 in June, according to the University of Michigan.

Coronavirus cases in the U.S. have risen to nearly 3.6 million, with deaths at 138,910 according to Johns Hopkins University. The U.S. leads the world in both categories.

Here are some of the big movers in the stock market Friday:

1. VBI Vaccines | Percentage Increase Over 24%

The Street Quant Ratings rate VBI Vaccines a Sell with a rating score of D.

Biopharma company VBI Vaccines  (VBIV) - Get Report continued to rise with other pharmaceutical stocks. 

2. Dynavax Technologies | Percentage Increase Over 19%

The Street Quant Ratings rate Dynavax Technologies a Sell with a rating score of D-.

Dynavax Technologies  (DVAX) - Get Report said on Friday it had entered into a  agreement with Icahn School of Medicine at Mount Sinai to develop a universal flu vaccine.

3. Novavax | Percentage Increase Over 16%

The Street Quant Ratings rate Novavax a Sell with a rating score of D-.

Novavax  (NVAX) - Get Report recently said that it was getting $1.6 billion from the U.S. government to develop a potential vaccine for covid-19..

4. Quidel | Percentage Increase Over 10%

The Street Quant Ratings rate Quidel Corp. a Buy with a rating score of A.

Quidel  (QDEL) - Get Report specializes in the diagnosis and detection of diseases and was one of the first companies to receive an emergency-use authorization from the Food and Drug Administration for a covid-19 diagnostic test.

5. Moderna | Percentage Increase Over 14%

The Street Quant Rating rates Moderna a Sell with a rating score of D+

Moderna  (MRNA) - Get Report was climbing Friday following a media report said that the company and other vaccine makers, including Sanofi  (SNY) - Get Report and Johnson & Johnson  (JNJ) - Get Report, were negotiating advance-purchase deals with the European Union.